All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

Rat soluble receptor activator of nuclear factor-kB ligand,sRANKL ELISA Kit

Citations (15) Protocol MSDS
Code CSB-E05126r
Size 96T,5×96T,10×96T
Price Request a Quote
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase within six months until depleted. More details >>
Interested in a trial size? Please leave a message below.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
tumor necrosis factor (ligand) superfamily, member 11
Alternative Names
Tnfsf11 ELISA Kit; Opgl ELISA Kit; Rankl ELISA Kit; Trance ELISA Kit; Tumor necrosis factor ligand superfamily member 11 ELISA Kit; Osteoclast differentiation factor ELISA Kit; ODF ELISA Kit; Osteoprotegerin ligand ELISA Kit; OPGL ELISA Kit; Receptor activator of nuclear factor kappa-B ligand ELISA Kit; RANKL ELISA Kit; TNF-related activation-induced cytokine ELISA Kit; TRANCE ELISA Kit; CD antigen CD254) [Cleaved into: Tumor necrosis factor ligand superfamily member 11 ELISA Kit; membrane form; Tumor necrosis factor ligand superfamily member 11 ELISA Kit; soluble form] ELISA Kit
Abbreviation
TNFSF11
Uniprot No.
Q9ESE2
Species
Rattus norvegicus (Rat)
Sample Types
serum, plasma, cell culture supernates
Detection Range
62.5 pg/mL-4000 pg/mL
Sensitivity
15.6 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cardiovascular
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of rat sRANKL in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
　SampleSerum(n=4)
1:1Average %95
Range %89-101
1:2Average %96
Range %91-105
1:4Average %97
Range %93-102
1:8Average %94
Range %90-99
Recovery
The recovery of rat sRANKL spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9489-100
EDTA plasma (n=4)10096-103
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
40001.934 1.829 1.882 1.719
20001.194 1.139 1.167 1.004
10000.753 0.733 0.743 0.580
5000.548 0.538 0.543 0.380
2500.385 0.375 0.380 0.217
1250.304 0.294 0.299 0.136
62.50.241 0.237 0.239 0.076
00.163 0.162 0.163 　
ELISA Data Analysis
ELISA Standard Curve & Curve Expert software
Troubleshooting
and FAQs
ELISA kit FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Shelf Life
6 months
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx.
Description

Tumor necrosis factor superfamily member 11 (TNFSF11), commonly known as RANKL, is a cytokine that regulates bone metabolism and immune system function. As a member of the TNF superfamily, TNFSF11 plays a central role in osteoclast differentiation and activation, making it a key mediator of bone resorption processes. Various cell types release the soluble form of this receptor activator of nuclear factor-κB ligand. It serves as an important biomarker in bone-related diseases and inflammatory conditions.

This quantitative sandwich ELISA kit measures rat soluble RANKL in serum, plasma, and cell culture supernatants with a detection range of 62.5 pg/mL to 4000 pg/mL and sensitivity of 15.6 pg/mL. The assay requires 50-100 μL sample volume and can be completed within 1-5 hours. Detection occurs at 450 nm wavelength, providing researchers with a reliable tool for quantifying TNFSF11 levels in Rattus norvegicus samples.

Application Examples

Note: The following application examples are drawn from a selection of publications citing this product. For additional applications, please refer to the full list of references in the "Citations" section.

This ELISA kit has been used in research examining bone metabolism and remodeling processes. Studies have applied the kit to measure RANKL levels in serum samples as part of comprehensive bone marker profiling, alongside other bone formation and resorption indicators.

• Orthodontic tooth movement research - Measuring RANKL levels during orthodontic treatment to understand bone remodeling mechanisms
• Bone metabolism studies - Quantifying RANKL as a key regulator of osteoclast activity in conjunction with other bone turnover markers
• Serum biomarker profiling - Measuring circulating RANKL levels to evaluate bone resorption processes in experimental models

Citations

Related Products

Tnfsf11 Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation.
Gene References into Functions
  1. results of this study concluded that the RANK, RANK-L and OPG system participates in bone remodeling after RME PMID: 29297549
  2. in this animal model the increase of RANK/RANKL and HGF markers is related to a specific immune response, and probably contributed to the evolution of periodontal disease PMID: 29211121
  3. In the supplemented and nonsupplemented rats groups, RANKL was upregulated compared with the control group. PMID: 28473060
  4. the canonical Wnt pathway inhibitor DKK1 blocked the osteogenesis effect and rescued the ratio of RANKL/OPG in periodontal ligament stem cells under force treatment for 1h PMID: 27154288
  5. study identified a number of differentially expressed bone-related mRNAs of potential significance and confirmed the osteoprotegerin/receptor activator of nuclear factor kappa-B (RANK)/RANK ligand (RANKL) pathway PMID: 25406873
  6. High-dose diosgenin treatment down-regulated expression of RANKL significantly in tibia from OVX rats compared to control. PMID: 25257532
  7. Data indicate that after loading jump (JL) for 6 weeks, the expressions of of interleukin 6 (IL-6), and ligand of receptor activator of NF-kappaB (RANKL) genes were markedly elevated in tibia. PMID: 25200151
  8. mechanical stimulation inhibits the activity of RANKL in rats PMID: 23553492
  9. Our findings indicate that the expression of RANKL in the occlusal portion of the bony crypt is unrelated to osteoclast recruitment and differentiation but is crucial to their activation during the creation of the eruption pathway. PMID: 23636419
  10. RANK and RANKL were expressed by T lymphocytes and macrophages in acute cellular kidney rejection after transplantation in rats PMID: 23769040
  11. In rheumatoid arthritis methotrexate/leflunomide combination therapy would relive the synovium hypertrophy through depressing cell viability and osteoclasia through decreasing RANKL and Il-17. PMID: 23334376
  12. There was no change in OPN expression after orthodontic retention and bone remodeling. PMID: 22353912
  13. the increase in RANK-RANKL expression is a response to podocyte injury, and RANK-RANKL may be a novel receptor-ligand complex for the survival response during podocyte injury. PMID: 22848465
  14. Insulin could promote osteoblastic differentiation of calcifying vascular smooth muscle cells by increased RANKL expression through ERK1/2 activation, but not PI3K/Akt activation. PMID: 22194983
  15. TRANCE/RANKL is constituively expressed by rat plasmacytoid dendritic cells. PMID: 22428075
  16. Pressure-overloaded myocardium generates RANKL, which induces inflammation mediators and myocardial inflammation. PMID: 22298642
  17. Bone loss and recovery in a receptor activator for nuclear factor kappa B ligand (RANKL)-administered rat model was assessed PMID: 20480144
  18. RANKL/OPG are key factors linking bone formation to resorption during bone remodeling. PMID: 21771583
  19. Vitamin C deficiency increased osteoclastogenesis by increasing RANK expression. PMID: 20444587
  20. These results suggest that antibody to RANKL can inhibit A. actinomycetemcomitans-specific T cell-induced periodontal bone resorption by blockade and reduction of tissue sRANKL. PMID: 21078845
  21. RANKL contributes to vascular calcification by regulating bone morphogenetic protein-2 and calcification inhibitor matrix Gla protein (MGP) expression, as well as bone-related proteins, and is counteracted by estrogen in a receptor-dependent manner. PMID: 20595654
  22. the toothless (tl) osteopetrotic rat mutation is not in the TNFSF11 locus PMID: 11804028
  23. accelerates nuclear translocation of nuclear factor kappa B in osteoclasts by elevaing cytosolic Ca2+ PMID: 12496256
  24. Effects of 12-O-tetradecanoylphorbol-13-acetate on osteoclastogenesis and its role in RANKL-induced signaling. PMID: 14672351
  25. RANK ligand is strongly up-regulated during acute heart allograft rejection; its blockade prolongs rat heart allograft survival. PMID: 14734743
  26. Detection of RANKL mRNA and protein in bone cells. PMID: 15704000
  27. Results suggest that the RANKL expressed in thymic epithelial cells plays a role in the development of T cells during thymic regeneration. PMID: 15844004
  28. Portasystemic shunting caused low turnover osteoporosis that was RANKL independent. PMID: 16874862
  29. Prolactin decreased RANKL mrna in cultured osteoblasts. PMID: 18432284
  30. These data indicate that serum 25-hydroxyvitamin D levels are a major determinant of osteoclastogenesis and bone mineral volume. PMID: 18597628
  31. Recombinant RANKL (rRANKL) mutants within the TNF-like core domain exhibited diminished osteoclastogenic potential as compared with wild-type rRANKL1 encoding the full TNF-like core domain [amino acids (aa) 160-318]. PMID: 19008464
  32. Orchiectomy increases the concentration of free sRANKL in bone marrow of aged rats. PMID: 19501680
  33. Bony spur formation can thus be considered a process that occurs independent of TNFalpha and RANKL and is triggered by destructive arthritis. PMID: 19714640

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type II membrane protein.; [Tumor necrosis factor ligand superfamily member 11, soluble form]: Secreted.
Protein Families
Tumor necrosis factor family
Tissue Specificity
Highly expressed in thymus and bone tissues.
Database Links
Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
Osteoprotegerin (OPG): What is Its Potential as a Biomarker or Therapeutic Target? Tumor Necrosis Factor Receptor Superfamily and Apoptosis Monoclonal Antibody Drugs Overview CD70 (CD27L/TNFSF7): a TNF Receptor Member, a “Star” Target for Clinical Research in Systemic Lupus Erythematosus (SLE), Arthritis, and Tumors! Does TNF Superfamily Inhibit Cancer or Promote Its Development? Tumor Necrosis Factor (TNF) Bispecific Antibody Overview: From Definition to Application ELISA Data Analysis How to Do The Pre-experiment before Your ELISA Experiment Four Types of ELISA 11 tips for choosing your right ELISA kit Do you Often Trouble in These Problems of ELISA? Problems and Solutions in ELISA Experiments
Related pathways
NF-kappa B signaling pathway Osteoclast differentiation
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy